What are the most important unanswered research questions on rapid review methodology? A James Lind Alliance research methodology Priority Setting Partnership: the Priority III study protocol [version 2; peer review: 2 approved, 2 approved with reservations] by Beecher, C. et al.
This is a repository copy of What are the most important unanswered research questions 
on rapid review methodology? A James Lind Alliance research methodology Priority 
Setting Partnership: the Priority III study protocol [version 2; peer review: 2 approved, 2 
approved with reservations].




Beecher, C., Toomey, E., Maeso, B. et al. (22 more authors) (2021) What are the most 
important unanswered research questions on rapid review methodology? A James Lind 
Alliance research methodology Priority Setting Partnership: the Priority III study protocol 
[version 2; peer review: 2 approved, 2 approved with reservations]. HRB Open Research, 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
STUDY PROTOCOL
   What are the most important unanswered research 
questions on rapid review methodology? A James Lind 
Alliance research methodology Priority Setting Partnership: 
the Priority III study protocol [version 2; peer review: 2 
approved, 2 approved with reservations]
Claire Beecher 1,2, Elaine Toomey 3, Beccy Maeso4, Caroline Whiting4, 
Derek C. Stewart 5, Andrew Worrall6,7, Jim Elliott6, Maureen Smith 8, 
Theresa Tierney9, Bronagh Blackwood 10, Teresa Maguire 11, 
Melissa Kampman12, Benny Ling12, Christopher Gravel13, Catherine Gill11, 
Patricia Healy 2, Catherine Houghton 2, Andrew Booth 14, 
Chantelle Garritty15, James Thomas16, Andrea C. Tricco17-19, Nikita N. Burke 1,2, 
Ciara Keenan 20, Matthew Westmore 21, Declan Devane 1,2,22
1Evidence Synthesis Ireland and Cochrane Ireland, Galway, Ireland 
2School of Nursing and Midwifery, National University of Ireland Galway, Galway, Ireland 
3School of Allied Health, University of Limerick, Limerick, Ireland 
4James Lind Alliance, University of Southampton, Southampton, UK 
5Honorary Professor, National University of Ireland Galway, Galway, Ireland 
6Public co-author, Evidence Synthesis Ireland, Galway, Ireland 
7Public co-author, Staffordshire, UK 
8Public co-author, Cochrane Consumer Network Executive, Ottawa, Canada 
9Patient Partner, HRB Primary Care Clinical Trials Network Ireland, Galway, Ireland 
10Wellcome-Wolfson Institute of Experimental Medicine, Queen's University Belfast, Belfast, UK 
11Health Research Board, Dublin, Ireland 
12Health Canada, Ottawa, Canada 
13School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada 
14School of Health And Related Research (ScHARR), University of Sheffield, Sheffield, UK 
15Public Health Agency of Canada, Ottawa, Canada 
16EPPI-Centre, UCL Social Research Institute, University College London, London, UK 
17Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health Toronto, Toronto, Ontario, 
Canada 
18Epidemiology Division and Institute for Health Policy, Management, and Evaluation, Dalla Lana School of Public Health, University 
of Toronto, Toronto, Ontario, Canada 
19Queen's Collaboration for Health Care Quality JBI Centre of Excellence, School of Nursing, Queen’s University, Kingston, Ontario, 
Canada 
20Campbell UK & Ireland, Queen's University Belfast, Belfast, UK 
21University of Southampton, Southampton, UK 
22Health Research Board- Trials Methodology Research Network, Galway, Ireland 
HRB Open Research
 
Page 1 of 24
HRB Open Research 2021, 4:80 Last updated: 29 NOV 2021
First published: 23 Jul 2021, 4:80  
https://doi.org/10.12688/hrbopenres.13321.1





Background: The value of rapid reviews in informing health care 
decisions is more evident since the onset of the coronavirus disease 
2019 (COVID-19) pandemic. While systematic reviews can be 
completed rapidly, rapid reviews are usually a type of evidence 
synthesis in which components of the systematic review process may 
be simplified or omitted to produce information more efficiently 
within constraints of time, expertise, funding or any combination 
thereof. There is an absence of high-quality evidence underpinning 
some decisions about how we plan, do and share rapid reviews. We 
will conduct a modified James Lind Alliance Priority Setting 
Partnership to determine the top 10 unanswered research questions 
about how we plan, do and share rapid reviews in collaboration with 
patients, public, reviewers, researchers, clinicians, policymakers and 
funders. 
Methods: An international steering group consisting of key 
stakeholder perspectives (patients, the public, reviewers, researchers, 
clinicians, policymakers and funders) will facilitate broad reach, 
recruitment and participation across stakeholder groups. An initial 
online survey will identify stakeholders’ perceptions of research 
uncertainties about how we plan, do and share rapid reviews. 
Responses will be categorised to generate a long list of questions. The 
list will be checked against systematic reviews published within the 
past three years to identify if the question is unanswered. A second 
online stakeholder survey will rank the long list in order of priority. 
Finally, a virtual consensus workshop of key stakeholders will agree on 
the top 10 unanswered questions. 
Discussion: Research prioritisation is an important means for 
minimising research waste and ensuring that research resources are 
targeted towards answering the most important questions. 
Identifying the top 10 rapid review methodology research priorities 
will help target research to improve how we plan, do and share rapid 
reviews and ultimately enhance the use of high-quality synthesised 
evidence to inform health care policy and practice.
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Introduction
Systematic reviews summarise existing research and use struc-
tured and ‘explicit methods to identify, select and critically 
appraise relevant studies, and collect and analyse data from 
these studies’1. Systematic reviews, therefore, provide a robust 
synthesis of existing research for a given topic and are typi-
cally seen as the cornerstone of research evidence for inform-
ing health policy and practice decision-making. However, 
systematic reviews require significant resources (time, exper-
tise, funding) to conduct and can take up to two years to 
complete2. While full systematic reviews can, and have been, 
completed rapidly, rapid reviews have emerged more com-
monly as a form of evidence synthesis in which certain 
steps of the systematic review process are omitted or simpli-
fied to produce information more efficiently within limited 
resources to inform healthcare decisions2,3.
Evidence suggests that rapid reviews are increasingly being 
commissioned, and the results used to inform decision making 
by policymakers and funders as a more resource efficient 
alternative to conventional systematic reviews4,5. The coronavi-
rus disease 2019 (COVID-19) pandemic has further increased 
the demand for rapid reviews due to the need to provide 
time-sensitive information to decision-makers6.
Although growing demand has led to a steady rise in rapid 
review publications generally since 20103,7, albeit often poorly 
reported with many important details not included8, there are 
challenges in identifying rapid reviews commissioned spe-
cifically by organisations as they are often not published in peer 
review journals3. This may, in part, be due to the suggestion that 
commissioned rapid reviews are considered more relevant in 
the context of narrow questions that address a specific ques-
tion that may be of relevance to that commissioning body alone, 
rather than broader questions of wider relevance that may 
require the focus of a conventional systematic review5,9. 
Despite an evident rise in the commissioning and conduct of 
rapid reviews, there is an absence of high-quality evidence 
underpinning some decisions about how they are planned, done 
and the findings shared. There is also limited evidence on 
the relative impact of different simplifications or omissions, 
for example, restricting searches to published material or by 
date/language or conducting single reviewer screening or data 
extraction10,11, on the validity and application of findings3 
commonly used in rapid reviews. Furthermore, there is no uni-
versally accepted definition of a rapid review3,6,12,13 and debate 
exists regarding the use of the word ‘rapid’, with several dif-
ferent synonyms previously identified within the literature7,10. 
These debates have been further complicated in the era of 
the COVID-19 pandemic where it has been highlighted that 
rapid reviews cannot be categorised simply based on the time 
taken to complete a review given that well-resourced con-
ventional systematic reviews have been conducted to a high 
standard, rapidly.
Overall, rapid reviews are ‘poorly understood, ill-defined 
diverse methodologies supported by limited published evi-
dence’3, with a need for further research to establish a robust 
methodological evidence base14. Without such an evidence 
base, the validity, appropriateness and usefulness of rapid 
reviews are undermined2. 
Research prioritisation plays a key role in minimising research 
waste by ensuring that research resources are targeted towards 
questions of the most potential benefit15. Research prioritisa-
tion involves identifying, prioritising and obtaining consensus 
on research needs and questions that are relevant and impor-
tant to all relevant stakeholders for that topic16. The James 
Lind Alliance (JLA) is a non-profit organisation that brings mul-
tiple stakeholders, including patients, carers and clinicians, 
together in an equal, transparent and evidence-based Priority 
Setting Partnership (PSP) to determine the most important 
evidence uncertainties or unanswered research questions. 
Although commonly focused on knowledge gaps surrounding 
the effects of treatments, the approach has been broadly 
applied to other areas such as diagnosis, prevention, and more 
recently, to identify methodology uncertainties in recruitment 
and retention within clinical trials17,18.
This Priority III PSP aims to identify the top 10 unanswered 
research questions about how we plan, do and share rapid 
reviews, as identified and prioritised by contributors drawn from 
key stakeholder groups, including patients, the public, reviewers, 
researchers, clinicians, policymakers and funders. Evidence 
Synthesis Ireland is conducting the Priority III PSP in 
collaboration with the JLA. Evidence Synthesis Ireland is an 
all-Ireland initiative funded by the Health Research Board and 
the Health and Social Care, Research and Development Divi-
sion of the Public Health Agency in Northern Ireland. It aims to 
make evidence syntheses better designed, conducted, reported, 
and more usable within health care policy and clinical prac-
tice decision-making by patients, the public, health care 
institutions and policymakers, clinicians and researchers.
Protocol
Ethical approval
Ethical approval was granted by the National University of Ireland 
Galway Research Ethics Committee (reference: 20-Apr-02).
          Amendments from Version 1
Protocol version 2 contains changes made in response to 
reviewers feedback on version 1.
This includes:
- Clarification on aspects such as the geographical spread of the 
steering group and participants generally in light of constructive 
comments from the reviewers.
- Grammatical errors identified by reviewers have been updated.
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James Lind Alliance PSP process
The study employs a PSP based on the methods of the JLA 
and will be reported following the REporting guideline for 
PRIority SEtting of health research (REPRISE) criteria16. 
Following the JLA Guidebook for PSPs19, this PSP will take 
place in seven stages and build on modified JLA guidance17,18 
and previous PSPs in recruitment and retention within clinical 
trials17,18. 
The seven stages of the project are: establishing the steer-
ing group, identifying and inviting potential partners, gathering 
uncertainties, data processing and verifying uncertainties, interim 
priority setting; final prioritisation workshop; and disseminating 
findings. 
This protocol was submitted prior to the consensus work-
shops and published after completion of the final prioritisation 
workshop. There are several factors that contributed to the 
late submission of the protocol. We had to balance the evolv-
ing nature of the PSP processes and having sufficient clarity 
on processes for inclusion in a protocol. We also encoun-
tered delays due to useful discussions with F1000/ HRB Open 
Research on affiliation of public partner authors and techni-
cal problems with submission attempts prior to the consensus 
workshop.
Establishing the Steering Group (6 months-January 2020). 
The Priority III PSP will be led and managed by an interna-
tional Steering Group who will coordinate, oversee and guide 
the PSP activities. The primary roles of the Steering Group 
will be to discuss and agree on the scope and remit of the 
project, enable access and reach to key stakeholder groups, 
contribute intellectually towards the study methods and inter-
pretation, and ensure that all perspectives are captured and 
meaningfully included throughout.
The Steering Group will also determine decisions about the 
processes used throughout as the project progresses. Mem-
bership of the Steering Group will include individuals and 
representatives from organisations, including patients and the 
public, reviewers, researchers, clinicians, policymakers and 
funders. The Steering Group will comprise of up 25 members 
across stakeholder groups. In line with the international 
relevance of the PSP topic, steering group members will be 
drawn from a wide geographical spread. Potential members 
will be approached to participate via email. Patient and public 
participants will be paid for their time spent on Steering Group 
activities. Other participants (researchers/ reviewers, clinicians, 
policy makers, funders) will not be paid.
Identifying and inviting potential partners (7 months-April 2020). 
Partners are organisations, groups and individuals impacted by 
how rapid reviews are planned, done and shared. They will com-
mit to supporting the PSP, promoting the process and encour-
aging their represented groups or members to participate19. 
Steering Group members will identify and engage additional 
appropriate partners through a process of peer knowledge 
and consultation, using the Steering Group members’ respec-
tive networks. Organisations and individuals who can reach 
and advocate for key stakeholder groups will be invited to 
participate with the PSP as partners. We have not set a mini-
mum or maximum number of partners we would like to 
recruit. Partners will be organisations or groups representative 
of diverse stakeholder perspectives (patients and the public, 
reviewers, researchers, clinicians, policymakers and funders) 
who will commit to supporting, participating and promoting 
the PSP among their stakeholder groups. As far as possible, 
the partners involved will seek to represent the interests of all 
stakeholders. All partners will be asked to confirm that they 
agree to support the PSP.
Gathering uncertainties (1 month- October 2020). The Rapid 
Review Methodology PSP will gather uncertainties from 
patients and the public, reviewers, researchers, clinicians, poli-
cymakers and funders. This will be undertaken by conducting 
an initial survey with all relevant stakeholders. The survey will 
identify unanswered questions or uncertainties about how we 
plan, do and share rapid reviews. The survey will be designed 
and piloted by the Steering Group members. The survey will 
be created using QuestionPro20 software and hosted on the 
Evidence Synthesis Ireland website. Participants will be asked 
to give their explicit consent to take part in the survey using 
yes/no questions. The survey will contain four open-ended 
questions. Three of the questions will focus on different stages 
of the rapid review process, and participants will be asked 
to answer as few or as many as they wish. The fourth ques-
tion asks for any additional questions or comments on the 
rapid review process. The four questions are;
1.     What questions or comments do you have about 
improving the process needed to plan a rapid review 
successfully?
2.     What questions or comments do you have about 
improving how rapid reviews are carried out?
3.     What questions or comments do you have about 
how the findings of rapid reviews are communicated to 
people?
4.     Do you have any other questions or comments on 
how we plan, do and share the results of rapid reviews?
Participant demographic data will also be collected to moni-
tor responses of different stakeholder groups and help 
refine and target the promotion of the survey towards 
under-represented groups if necessary. In line with previous 
methodology-focused PSPs17,18, the survey will be open for 
four weeks.
The survey will be advertised and distributed via the Steer-
ing Group and the PSP Partners. Specifically, members will 
distribute the survey via their networks, mailing lists, news-
letters and social media. We do not have an a priori deter-
mined sample size and instead will distribute the survey 
widely with a view to reaching as wide an audience as pos-
sible. The survey and all other study materials can be found 
as Extended data21.
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Data processing and verifying uncertainties (5 months 
- November 2020). The initial survey consultation process 
is expected to produce substantial ‘raw’ questions and com-
ments indicating stakeholders’ areas of uncertainty. The survey 
data will be downloaded from QuestionPro20. These raw ques-
tions will be categorised and refined by the National University 
of Ireland, Galway research team (CB, CH, DD) into summary 
questions that are clear, addressable by research, and under-
standable to all. Similar or duplicate responses will be com-
bined where appropriate. Questions will be considered out of 
scope if they do not relate to planning, doing and sharing the 
results of rapid reviews within healthcare. We defined health-
care a priori as being related to the “treatment, control or pre-
vention of disease, illness, injury or disability, and the care or 
aftercare of a person with these needs (whether or not the tasks 
involved have to be carried out by a health professional)”22. 
Questions will also be considered out of scope if they are 
asking for information or advice, or being too broad, unclear, 
unrelated or off topic. Questions deemed to be out of scope will 
be compiled separately and made available for future use upon 
request.
The Steering Group will exercise oversight on data analy-
sis and processing to ensure that the raw data are being inter-
preted appropriately. The summary questions will be developed 
in a reflective manner that is understandable to all audiences. 
The process will be conducted transparently to ensure that 
the finalised questions can be traced back to the raw response 
data.
Each in-scope question will be checked against existing 
sources of evidence to determine which questions remain unan-
swered. A question will be verified as unanswered if a synthesis 
gap is apparent following a search of all relevant system-
atic reviews published within the past three years. We judged 
a review to be systematic when it involved explicit methods 
to search, select, critically appraise and synthesise individual 
studies. If a systematic review has been conducted to answer 
any of the questions completely, the quality of that system-
atic review will be appraised using the AMSTAR 223 tool to 
help inform decisions about the extent to which the question 
has been answered. If, following use of the AMSTAR 2 tool, a 
systematic review conducted to answer a question completely 
is identified as being of high quality (between 8–11), the question 
will be deemed as answered. Evidence checking will be 
completed by one researcher (CB) and verified by one other 
researcher (DD) Difference of opinion will be resolved by 
consultation with a third researcher if necessary.
Existing sources of evidence will be identified through a 
search of the PubMed bibliographic database for systematic 
reviews published from 2018 to the time of searching (2021) 
using a search strategy developed specifically for use in 
this project with the support of an experienced information 
specialist (see Table 1 for search strategy and limits applied). 
Due to limited resources (time and unavailability of translator) 
grey literature and publications not available in English will 
be excluded.
The JLA Question Verification Form, which describes the proc-
ess used to verify question uncertainty, will be completed. 
In line with JLA guidance, the Question Verification Form 
includes details of the types and sources of evidence used to 
check uncertainty. This form will be published on the JLA 
website to enable stakeholders to understand how the PSP 
decided that these questions are unanswered and any limitations 
of this process.
The Steering Group will be asked to review and refine, as appro-
priate, the final list of summary questions for inclusion in 
the interim survey.
Interim priority setting (1 month- April 2021). Interim priority 
setting is where the long list of questions is reduced to a shorter 
list that can be taken to the final priority setting workshop. 
This shortlist is aimed at a wide audience and will be admin-
istered using an electronic survey (QuestionPro software20) 
and hosted on the Evidence Synthesis Ireland website. It will 
be designed and piloted by the Steering Group members. In 




(((“Systematic Reviews as Topic” OR “Meta-Analysis as Topic” OR “Review Literature as Topic”) AND “METHODS”[SH]) 
OR ((“Syst Rev”[TA] OR “J Clin Epidemiol”[TA] OR “Res Synth Methods”[TA]) AND “METHODS”[SH]) OR ((“Rapid Reviews” 
OR “systematic reviews” OR “systematic literature reviews”) AND “METHODS”[SH] AND (“literature search*” OR 
Information Storage and Retrieval)) OR ((“Rapid Reviews” OR “systematic reviews” OR “systematic literature reviews”) 
AND “METHODS”[SH] AND (“plain language summar*” OR “lay summar*”)) OR ((“Rapid Reviews” OR “systematic 
reviews” OR “systematic literature reviews”) AND “METHODS”[SH] AND “strength of evidence”)) OR ((“Rapid Reviews” 
OR “systematic reviews” OR “systematic literature reviews”) “METHODS”[SH] AND “study selection”)) OR ((“Rapid 
Reviews” OR “systematic reviews” OR “systematic literature reviews”) AND “METHODS”[SH] AND “data extraction”)) 
OR ((“Rapid Reviews” OR “systematic reviews” OR “systematic literature reviews”) AND “METHODS”[SH] AND “quality 
assessment”)) OR ((“Rapid Reviews” OR “systematic reviews” OR “systematic literature reviews”) AND “METHODS”[SH] 
AND “critical appraisal”))) NOT Protocol[TI])
Limit 1 Limited to ‘review’ and ‘systematic review’
Limit 2 Limited to three years prior to search taking place
Limit 3 Limited to English
TA represents journal title abbreviation. SH represents subheading
Page 6 of 24
HRB Open Research 2021, 4:80 Last updated: 29 NOV 2021
questions developed from the initial survey in order of impor-
tance. This interim priority setting process will help reduce 
the long list to a short, manageable set of approximately 20 
indicative questions that are clear, addressable by research and 
understandable. The survey will be open for four weeks and 
will be advertised and distributed like the initial survey via 
the Steering Group and the PSP Partners. Participant demo-
graphic data will be collected to monitor response rates 
from different stakeholder groups to help refine and target 
the promotion of the survey towards under-represented groups.
Questions prioritised in the interim survey will go forward 
for final prioritisation at a stakeholder workshop(s). Where 
the interim prioritisation does not produce a clear ranking or 
cut off point, the Steering Group will decide, and report, 
which questions are taken forward to the final prioritisation.
Final prioritisation workshop (2 days- May 2021). The final pri-
ority setting stage will involve two half-day virtual workshops 
facilitated by the JLA to ensure transparency, accountability, 
fairness and appropriate representation. Based on the meth-
ods of the JLA, these workshops would ordinarily take place 
in person, but due to the Priority III study being conducted 
under restrictions contingent upon the global COVID-19 
pandemic, the workshops will be held virtually. With input 
from the Steering Group, up to 24 contributors drawn from 
key stakeholder groups (patients, public, reviewers, research-
ers, clinicians, policymakers and funders) from a wide 
geographical spread, will be recruited to participate in a day 
of group discussion, plenary sessions and ranking exercises to 
determine the top 10 questions for research. Four virtual brea-
kout rooms will be used to facilitate smaller group discus-
sions. All participants will declare their interests, enabling a 
diverse group of stakeholders to exchange knowledge, perspec-
tives, and experiences and inform the decision-making process. 
A maximum of four Steering Group members will be invited to 
participate in the workshops, with a steering group mem-
ber in each breakout room to participate and answer any 
questions about the Priority III process. Additional Steering 
Group members who wish to attend will do so in an observer 
capacity. The outcome of the workshop will be consensus on 
a top 10 list of research priorities of unanswered questions 
about rapid review methodology.
Disseminating findings. The results of the study will be 
disseminated through the JLA and Evidence Synthesis 
Ireland websites. The Steering Group will identify additional 
appropriate audiences to engage when sharing the results, 
such as researchers, funders, and patient and clinical commu-
nities. The steering group will also identify opportunities to 
collaborate and contribute evidence to answer the top 10 list 
of research priorities.
Conclusion
The Priority III study will identify a top 10 of unanswered 
research questions regarding rapid review methodology, guided 
by an adaptation of the James Lind Alliance PSP process. 
The findings of the study will contribute to minimising research 
waste in rapid review methodology, ensuring that research 
resources will be used to answer questions on this topic that 
have been prioritised by key stakeholders internationally, 
including patient and the public, reviewers, researchers, 
clinicians, policymakers and funders. 
Study status
At the time of submission, all stages up to the dissemination of 
findings had been completed. There are several factors that 
contributed to the submission of the protocol at this time:
1.     The iterative nature of the PSP processes and the deci-
sions that needed to be made by the Steering Group as 
the study progresses through to the later stages
2.     Discussions with F1000/ HRB Open Research on 
affiliation of authors and the time dedicated to same
No results of the study have yet been disseminated.
Data availability
Underlying data
No data are associated with this article.
Extended data
Open Science Framework: Priority III. https://doi.org/10.17605/
OSF.IO/R6VFX21.
This project contains the following extended data:
-     Survey 1
○     Initial survey analysis Priority III.pdf (table 
used for analysis)
○     Initial survey download.pdf (survey)
○     Initial survey Priority III PIL.pdf (participant 
information leaflet)
○     Verification of summary questions.xlsx
-      Survey 2
○     Interim survey analysis Priority III.pdf (table 
used for analysis)
○     Interim survey Priority-III-PIL.pdf (participant 
information leaflet)
-     Workshop materials
○     Meeting consent form Priority III.pdf
○     Meeting PIL Priority III.pdf
○     Participant Worksheet.pdf
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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I am satisfied that the authors have adequately responded to my concerns about the paper. 
 
In relation to their response to my second point about the use of AMSTAR 2: the authors clarified 
that they will use a rating of 8-11 to classify a systematic review as high quality but I am a little 
perplexed as to how this will work in practice as AMSTAR 2 has 16 items and is not intended to 
generate an overall score. However, I am happy for the authors to clarify this in any resulting 
publications of results.
 
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: I have experience in conducting both systematic reviews and rapid reviews. I 
have also been involved in the development and assessment of methodologies for rapid reviews.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard.
Version 1
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Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Yaolin Zhou   
Department of Pathology & Laboratory Medicine, Brody School of Medicine, East Carolina 
University, Greenville, NC, USA 
Despite the increasing need and use of “rapid reviews” during the COVID-19 pandemic, the 
evidence behind these abbreviated reviews themselves, is rather scant. The authors, who are 
presumably members of the James Lind Alliance (JLA), propose a research prioritization study 
(Priority Setting Partnership), which consists of two stakeholder surveys, followed by a consensus 
workshop to identify the top 10 unanswered questions regarding rapid reviews. 
 
The steps described in the paper include:
Establishing a steering group (6 months) to oversee the PSP. The steering group includes 
members across stakeholder groups and are reasonable for the project activities. 
 
1. 
Identifying and inviting potential partners (7 months). The authors state that there is no 
minimum or maximum number of partners. Patient and public partners will be reimbursed 




Gathering uncertainties (1 month – Oct 2020) from patients and the public, reviewers, 
researchers, clinicians, policymakers and funders (by conducting an initial 4 question survey 
with all relevant stakeholders). 
 
3. 
Data processing and verifying uncertainties (5 months) – raw questions will be categorized 
and refined into summary questions (downloaded from QuestionPro and then categorized 
and refined by a “NUI Galway” research team. 
 
4. 
Interim priority setting ( 1 month – April 2021) – long list of questions is reduced to shorter 
list. Stakeholders will be asked to prioritize summary questions. 
 
5. 
Final prioritization workshop (2 days – May 2021) – two half day virtual workshops of up to 
24 key stakeholder members to participate in discussions (group discussion, plenary 
sessions, raking exercises, virtual breakout rooms). The outcome of the workshop will be 








The paper is written in the future tense, but all steps except for 7 above, have already been 
completed per the authors. Throughout my reading, I am anticipating that this is a future 
study that has yet to be conducted. It comes as a surprise to me that at the very end, in the 
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have been completed.
Minor Concerns
Minor grammatical error: “Evidence suggests that rapid reviews are increasingly being 
commissioned, and the results used, to inform decision making by policymakers ….” Please 
remove the comma after “results used.” The sentence should read: “Evidence suggests that 
rapid reviews are increasingly being commissioned, and the results used to inform decision 
making by policymakers…” 
 
○
Presumably the authors of the paper are on the steering group? This is not clearly stated. 
 
○
NUI Galway needs to be spelt out for readers unfamiliar that it represents National 
University of Ireland, Galway. 
 
○
The authors do not state how much the partners will be reimbursed. 
 
○
The time frames for the initial steps listed above are inconsistent. Some are written to only 
include the duration, but others include both duration (e.g., 1 month, 6 months, 2 days) and 
the month (Oct 2020, April 2021, May 2021). My recommendation would be to stick with one 
approach and be consistent (e.g., include the time period with actual dates because the 
duration can be implied).
○
Summary 
This paper describes a proposed research project that consists of a series of focus groups and 
stakeholder meetings to define the most critical 10 research questions regarding rapid reviews. It 
is well-written with minimal grammatical and syntax errors, but I am unclear why it was written in 
the future tense. The authors describe a proposed study, when in fact, all steps of the project have 
been conducted except for the last one. When I get to the final section of the paper and realize the 
proposed steps have been completed, my natural questions include; How did the sessions go? 
Who was recruited to participate? How many were recruited and what was the breakdown? How 
much were the participants reimbursed for their time? What did the questions reveal? What are 
the next steps? But these questions are unanswered by the authors because the paper is written 
as a proposed project, despite the steps having already been completed. This issue needs to be 
resolved before I am fully comfortable with accepting in the current state. 
 
Recommendation 
Thank you for the opportunity to review this paper. My recommendation would be to convert this 
into a dissemination paper, such as the PRioRiTy (Prioritising Recruitment in Randomised Trials) 
publications the authors cite (references 17 and 18). If one of the purposes of the project is to 
conduct research on the top 10 list of research priorities of unanswered questions about rapid 
review methodologies AND then disseminate those findings, then the authors may want to 
consider converting their paper into one that serves the latter purpose.
 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
HRB Open Research
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Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Molecular diagnostics, health policy, diagnostic testing, healthcare value, test 
utilization
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 05 Nov 2021
Claire Beecher, Evidence Synthesis Ireland and Cochrane Ireland, Galway, Ireland 
Reviewer Comment 1 
The paper is written in the future tense, but all steps except for 7 above, have already been 
completed per the authors. Throughout my reading, I am anticipating that this is a future 
study that has yet to be conducted. It comes as a surprise to me that at the very end, in the 
“study status,” the authors reveal all the steps except the final one (disseminating findings), 
have been completed. 
 
Response 1 
Thank you for raising this point. This protocol paper gives much more detail on the methods 
than will be contained in the results paper hence the importance of this protocol paper. 
 
There are several factors that contributed to the submission of the protocol at this time:
The evolving nature of the PSP process and the decisions that needed to be made by 
the steering group as the study progresses through to the later stages. 
 
1. 
Discussions with F1000/ HRB Open Research on affiliation of public partner authors 
and the time to agree same. 
 
2. 
Attempts were made to be submit the protocol prior to the completion of the 
workshop but due to an issue with submission process, this was not possible until 
after the workshop had been completed (issue rectified by HRB Open Research).
3. 
Although the protocol would ideally have been submitted at an earlier stage, this was not 
possible given the above factors. 
 
We have retained future tense in keeping with protocols papers but have added the 
following to the paper to be more transparent: 
 
'This protocol was submitted prior to the consensus workshops and published after 
completion of the final prioritisation workshop. There are several factors that contributed to 
the late submission of the protocol. We had to balance the evolving nature of the PSP 
HRB Open Research
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processes and having sufficient clarity on processes for inclusion in a protocol. We also 
encountered delays due to useful discussions with F1000/ HRB Open Research on affiliation 
of public partner authors and technical problems with submission attempts prior to the 
consensus workshop’ (4th paragraph under heading ‘James Lind Alliance PSP process’) 
 
Reviewer Comment 2 
Minor grammatical error: “Evidence suggests that rapid reviews are increasingly being 
commissioned, and the results used, to inform decision making by policymakers ….” Please 
remove the comma after “results used.” The sentence should read: “Evidence suggests that 
rapid reviews are increasingly being commissioned, and the results used to inform decision 
making by policymakers…” 
 
Response 2 
Thank you very much for highlighting this, it has now been amended. 
 
Reviewer Comment 3  
Presumably the authors of the paper are on the steering group? This is not clearly stated. 
 
Response 3 
Not all co-authors are members of the steering group. All co-authors have been included 
based on their contribution as identified using the CREDiT Taxonomy. 
 
Reviewer Comment 4 
NUI Galway needs to be spelt out for readers unfamiliar that it represents National 
University of Ireland, Galway. 
 
Response 4 
Thank you very much, this has now been updated. 
 
Reviewer Comment 5 
The authors do not state how much the partners will be reimbursed. 
 
Response 5 
This has not been stated as there is no reimbursement for partners. 
 
Reviewer Comment 6 
The time frames for the initial steps listed above are inconsistent. Some are written to only 
include the duration, but others include both duration (e.g., 1 month, 6 months, 2 days) and 
the month (Oct 2020, April 2021, May 2021). My recommendation would be to stick with one 
approach and be consistent (e.g., include the time period with actual dates because the 
duration can be implied). 
 
Response 6 
Thank you for pointing this out - this has now been updated as suggested (please note 
some overlap in timeline included between establishing steering group and identifying and 
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Reviewer Comment 7 
This paper describes a proposed research project that consists of a series of focus groups 
and stakeholder meetings to define the most critical 10 research questions regarding rapid 
reviews. It is well-written with minimal grammatical and syntax errors, but I am unclear why 
it was written in the future tense. The authors describe a proposed study, when in fact, all 
steps of the project have been conducted except for the last one. When I get to the final 
section of the paper and realize the proposed steps have been completed, my natural 
questions include; How did the sessions go? Who was recruited to participate? How many 
were recruited and what was the breakdown? How much were the participants reimbursed 
for their time? What did the questions reveal? What are the next steps? But these questions 
are unanswered by the authors because the paper is written as a proposed project, despite 
the steps having already been completed. This issue needs to be resolved before I am fully 
comfortable with accepting in the current state. 
 
Response 7 
Thank you for raising this feedback. Response to the point has been provided in point 1. 
 
Reviewer Comment 8 
Thank you for the opportunity to review this paper. My recommendation would be to 
convert this into a dissemination paper, such as the PRioRiTy (Prioritising Recruitment in 
Randomised Trials) publications the authors cite (references 17 and 18). If one of the 
purposes of the project is to conduct research on the top 10 list of research priorities of 
unanswered questions about rapid review methodologies AND then disseminate those 
findings, then the authors may want to consider converting their paper into one that serves 
the latter purpose 
 
Response 8 
Thank you very much for your time reviewing this protocol. We do take on board your 
feedback and although ideally the protocol would have been submitted at an earlier stage, 
this was not possible given the factors that have been listed above. 
 
This protocol paper gives much more detail on the methods than will be contained in the 
results paper hence the importance of this protocol paper. We have retained future tense in 
keeping with protocols papers but have added the following to the paper to be more 
transparent: 
 
'This protocol was submitted prior to the consensus workshops and published after 
completion of the final prioritisation workshop. There are several factors that contributed to 
the late submission of the protocol. We had to balance the evolving nature of the PSP 
processes and having sufficient clarity on processes for inclusion in a protocol. We also 
encountered delays due to useful discussions with F1000/ HRB Open Research on affiliation 
of public partner authors and technical problems with submission attempts prior to the 
consensus workshop’ (4th paragraph under heading ‘James Lind Alliance PSP process’)  
Competing Interests: No competing interests were disclosed.
HRB Open Research
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Reviewer Report 11 October 2021
https://doi.org/10.21956/hrbopenres.14503.r30327
© 2021 Haby M. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Michelle Haby   
1 Department of Chemical and Biological Sciences, Universidad de Sonora, Hermosillo, Sonora, 
Mexico 
2 Centre for Health Policy, Melbourne School of Population and Global Health, The University of 
Melbourne, Melbourne, Australia 
This is a very interesting and valuable project. It has a well-described and well written 
methodology for priority setting. The results will provide an important contribution to the field. I 
do have some comments, however, for consideration: 
 
I was rather surprised to reach the end of the protocol and find out that the research had already 
been completed, except for the dissemination of the findings. It made me wonder what then the 
purpose of peer review was, except perhaps to ensure accuracy of reporting. While I imagine that 
there are good reasons for the protocol being submitted at this late stage, I think it would be 
more transparent (and helpful for the reader) that this is made clear from the beginning, along 
with the reason. Thus, I suggest that the protocol should be written in the past tense, where 
applicable, and dates added for all stages. 
 
The inclusion of the process for checking that questions were indeed still unanswered is a very 
valuable inclusion in the methods – I look forward to seeing the results of this process. I hope that 
the authors can include in the publication of the results the questions that are already answered 
and the sources of the existing evidence. I do have some concerns about the methodology here 
and suggest that the authors include a justification of their choice of methods or further 
clarification:
The quality of the systematic reviews will be appraised using AMSTAR 2 but there is no 
description in the protocol as to how the score will be used in deciding if the question has 
been answered, e.g. does it need to have a minimum quality? 
 
○
Only PubMed will be searched and only reviews published in English will be included. It is 
not clear how many reviewers will be involved in the quality assessment and why non-
English and grey literature is not being included. If the authors were to evaluate their own 
review process using AMSTAR 2 I expect that it would not score highly. Thus, the authors 
should provide greater clarity and a justification for their choice of methods for this part of 
the protocol.
○
In the paragraph headed ‘Data processing and verifying uncertainties (5 months)’ I noticed that 
the scope of the priority setting exercise is limited to the healthcare setting. This is a very 
important limitation but no explanation is given for why. Why not include public health or health 
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It is not clear from the protocol if there was any attempt to include the views of people from low- 
to middle-income countries, which may be able to offer a broader perspective of the unanswered 
questions. Can this be clarified? 
 
When defining rapid reviews (in the abstract and introduction) I suggest noting that an important 
distinction from systematic reviews is that rapid reviews are generally conducted with the needs of 
decision-makers in mind – see for example:
Hartling L, Guise JM, Kato E, Anderson J, Aronson N, Belinson S, et al. EPC Methods: An 
Exploration of Methods and Context for the Production of Rapid Reviews. Research White 
Paper. Prepared by the Scientific Resource Center under Contract No. 290-2012-00004-C. 




Haby MM, Chapman E, Clark R, Barreto J, Reveiz L, Lavis JN. What are the best 
methodologies for rapid reviews of the research evidence for evidence-informed decision 




Third paragraph of introduction: 1) in the first sentence it is not clear what is ‘often poorly 
reported’, and 2) the last sentence doesn’t make sense to me. Consider revising both. 
 
○




1. Hartling L, Guise JM, Kato E, Anderson J, et al.: EPC Methods: An Exploration of Methods and 
Context for the Production of Rapid Reviews. PubMed Abstract 
2. Haby MM, Chapman E, Clark R, Barreto J, et al.: What are the best methodologies for rapid 
reviews of the research evidence for evidence-informed decision making in health policy and 
practice: a rapid review.Health Res Policy Syst. 2016; 14 (1): 83 PubMed Abstract | Publisher Full Text  
 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Yes
Competing Interests: I have a professional interest in rapid review methods and have written on 
the subject in both peer-reviewed journal papers and in a paid capacity for WHO/PAHO.
Reviewer Expertise: I have experience in conducting both systematic reviews and rapid reviews. I 
HRB Open Research
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have also been involved in the development and assessment of methodologies for rapid reviews.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 05 Nov 2021
Claire Beecher, Evidence Synthesis Ireland and Cochrane Ireland, Galway, Ireland 
Reviewer Comment 1 
I was rather surprised to reach the end of the protocol and find out that the research had 
already been completed, except for the dissemination of the findings. It made me wonder 
what then the purpose of peer review was, except perhaps to ensure accuracy of reporting. 
While I imagine that there are good reasons for the protocol being submitted at this late 
stage, I think it would be more transparent (and helpful for the reader) that this is made 
clear from the beginning, along with the reason. Thus, I suggest that the protocol should be 
written in the past tense, where applicable, and dates added for all stages. 
 
Response 1 
Thank you for raising this point. This protocol paper gives much more detail on the methods 
than will be contained in the results paper hence the importance of this protocol paper. 
 
There are several factors that contributed to the submission of the protocol at this time:
The evolving nature of the PSP process and the decisions that needed to be made by 
the steering group as the study progresses through to the later stages. 
 
1. 
Discussions with F1000/ HRB Open Research on affiliation of public partner authors 
and the time to agree same. 
 
2. 
Attempts were made to be submit the protocol prior to the completion of the 
workshop but due to an issue with submission process, this was not possible until 
after the workshop had been completed (issue rectified by HRB Open Research).
3. 
Although the protocol would ideally have been submitted at an earlier stage, this was not 
possible given the above factors. 
 
We have retained future tense in keeping with protocols papers but have added the 
following to the paper to be more transparent: 
 
'This protocol was submitted prior to the consensus workshops and published after 
completion of the final prioritisation workshop. There are several factors that contributed to 
the late submission of the protocol. We had to balance the evolving nature of the PSP 
processes and having sufficient clarity on processes for inclusion in a protocol. We also 
encountered delays due to useful discussions with F1000/ HRB Open Research on affiliation 
of public partner authors and technical problems with submission attempts prior to the 
consensus workshop’ (4th paragraph under heading ‘James Lind Alliance PSP process’) 
 
Reviewer Comment 2 
HRB Open Research
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The inclusion of the process for checking that questions were indeed still unanswered is a 
very valuable inclusion in the methods – I look forward to seeing the results of this process. 
I hope that the authors can include in the publication of the results the questions that are 
already answered and the sources of the existing evidence. I do have some concerns about 
the methodology here and suggest that the authors include a justification of their choice of 
methods or further clarification:
The quality of the systematic reviews will be appraised using AMSTAR 2 but there is 
no description in the protocol as to how the score will be used in deciding if the 
question has been answered, e.g. does it need to have a minimum quality? 
 
○
Only PubMed will be searched and only reviews published in English will be included. 
It is not clear how many reviewers will be involved in the quality assessment and why 
non-English and grey literature is not being included. If the authors were to evaluate 
their own review process using AMSTAR 2 I expect that it would not score highly. 
Thus, the authors should provide greater clarity and a justification for their choice of 
methods for this part of the protocol.
○
Response 2 
Thank you for this comment. Yes, in the final paper all results and original documents used 
will be presented via a link to Open Science Framework to ensure transparency of this 
process.
The following text has been included in relation to how the AMSTAR 2 score would be 
used in deciding if a question is answered: ‘If, following use of the AMSTAR 2 tool, a 
systematic review conducted to answer any of the questions completely is identified 
as being of high quality (between 8-11), the question will be deemed as answered.’ (3
rd paragraph under heading ‘Data processing and verifying uncertainties’).
○
It is stated that “Evidence checking will be completed by one researcher (CB) and 
verified by one other researcher (DD) Difference of opinion will be resolved by 
consultation with a third researcher if necessary” (3rd paragraph under heading ‘Data 
processing and verifying uncertainties’).
○
Thank you very much for highlighting this omission. A rationale for non-English and grey 
literature not being included has been added to the text (4th paragraph under heading ‘Data 
processing and verifying uncertainties’). 
 
Reviewer Comment 3  
In the paragraph headed ‘Data processing and verifying uncertainties (5 months)’ I noticed 
that the scope of the priority setting exercise is limited to the healthcare setting. This is a 
very important limitation but no explanation is given for why. Why not include public health 
or health system questions, which are equally (if not more) important for rapid reviews? 
 
Response 3 
We wish to clarify that we had a relatively broad definition of healthcare which we defined a 
priori as being; 
 
“treatment, control or prevention of disease, illness, injury or disability, and the care or 
aftercare of a person with these needs (whether or not the tasks involved have to be carried 
out by a health professional)”. This definition has been adapted from the UK Department of 
Health and Social Care guidance document titled ‘National Framework for NHS Continuing 
HRB Open Research
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Healthcare and NHS-funded Nursing Care’. 
 
We have added this to the paper (1st paragraph under heading ‘Data processing and 
verifying uncertainties’). 
 
Reviewer Comment 4 
It is not clear from the protocol if there was any attempt to include the views of people from 
low- to middle-income countries, which may be able to offer a broader perspective of the 
unanswered questions. Can this be clarified? 
 
Response 4 
The views of people from low- to middle-income countries are very important in each stage 
of the Priorty III stages. 
 
Reference to the importance of representation from underrepresented groups has been 
highlighted by the statement “Participant demographic data will also be collected to 
monitor responses of different stakeholder groups and help refine and target the 
promotion of the survey towards under-represented groups if necessary” within the 
gathering uncertainties and interim priority setting headings/ stages. 
 
The final prioritisation workshop stage has been updated to highlight that workshop 
participants will be drawn from a wide geographical spread including representation from 
low-middle income countries. 
 
Reviewer Comment 5 
When defining rapid reviews (in the abstract and introduction) I suggest noting that an 
important distinction from systematic reviews is that rapid reviews are generally conducted 
with the needs of decision-makers in mind – see for example:
Hartling L, Guise JM, Kato E, Anderson J, Aronson N, Belinson S, et al. EPC Methods: An 
Exploration of Methods and Context for the Production of Rapid Reviews. Research 
White Paper. Prepared by the Scientific Resource Center under Contract No. 290-
2012-00004-C. AHRQ Publication No. 15-EHC008-EF. Rockville, MD: Agency for 
Healthcare Research and Quality; 20151.
○
Haby MM, Chapman E, Clark R, Barreto J, Reveiz L, Lavis JN. What are the best 
methodologies for rapid reviews of the research evidence for evidence-informed 




Thank you for this feedback, however we do feel that the point you have raised is addressed 
in the first two paragraphs of the introduction. For example, we say (paragraph 1 & 2 of 
introduction), 
 
“While full systematic reviews can, and have been, completed rapidly, rapid reviews have 
emerged more commonly as a form of evidence synthesis in which certain steps of the 
systematic review process are omitted or simplified to produce information more efficiently 
within limited resources to inform healthcare decisions. 
Evidence suggests that rapid reviews are increasingly being commissioned, and the results 
HRB Open Research
 
Page 19 of 24
HRB Open Research 2021, 4:80 Last updated: 29 NOV 2021
used to inform decision making by policymakers and funders as a more resource efficient 
alternative to conventional systematic reviews…..” 
 
Reviewer Comment 6 
Third paragraph of introduction: 1) in the first sentence it is not clear what is ‘often poorly 
reported’, and 2) the last sentence doesn’t make sense to me. Consider revising both. 
 
Response 6 
Thank you very much for this feedback- both sentences have been updated (paragraph 3 of 
introduction) 
 
Reviewer Comment 7 
Under ‘Gathering uncertainties…’ – ‘content’ instead of ‘consent’ is used. 
 
Response 7 
Thank you very much for highlighting this, it has now been amended (paragraph 1 under 
heading ‘Gathering uncertainties’)  
Competing Interests: No competing interests were disclosed.
Reviewer Report 01 October 2021
https://doi.org/10.21956/hrbopenres.14503.r30325
© 2021 O'Leary T. This is an open access peer review report distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
Timothy O'Leary   
1 Veterans Health Administration, Washington, DC, USA 
2 University of Maryland School of Medicine, Baltimore, MD, USA 
The paper provides a well-structured and readable overview of a project intended to develop a 
better understanding of the strengths and limitations of “rapid reviews,” and presumably provide 
a framework for better standardizing this form of evidence synthesis. 
 
I note that according to the authors “At the time of submission, all stages up to the dissemination of 
findings had been completed.” 
 
Normally I would expect the material in the current paper to be included in the final publication, 
rather than in a separate protocol paper that seems to have been written essentially 
contemporaneously with the final work.  I will not second-guess this decision, but will instead 
comment as if the project were not now largely complete. 
 
There are a few places where I believe that the reader’s understanding of the project could be 
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improved by including either tables or supplementary material to improve the specificity of the 
document.  The document states that: 
 
"Membership of the Steering Group will include individuals and representatives from organisations, 
including patients and the public, reviewers, researchers, clinicians, policymakers, and funders. The 
Steering Group will comprise of up 25 members across stakeholder groups." 
 
Either the membership of this Steering group should be provided, or the types of groups and 
organizations that were contacted to participate should be provided. Were these groups restricted 
to Ireland, or to Europe, or to English speaking countries, or to advanced economies?  It seems 
likely that the ultimate product coming from a Eurocentric steering committee will be different 
than that which involves individuals from Asia, Africa, and South America. On the other hand, it 
would be difficult to adequately represent researchers, clinicians, policymakers, and funders 
across a wide geographic distribution.    
 
The areas of expertise associated with steering group members (statistics, survey methodology, 
etc.) should be described in more detail. 
 
Similarly, the nature of the “partners”  should also be better defined, as should a bit about the 
total number of stakeholders expected to participate.  The final report should include information 
on the nature and number of stakeholders that were contacted and who declined to participate.
 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
No
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: I currently perform systematic reviews and meta-analysis for covid19-related 
diagnostics.  I have previous experience in randomized clinical trials, genomic epidemiology, and 
preclinical research.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 05 Nov 2021
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Claire Beecher, Evidence Synthesis Ireland and Cochrane Ireland, Galway, Ireland 
Reviewer Comment 1 
I note that according to the authors “At the time of submission, all stages up to the 
dissemination of findings had been completed.” 
 
Normally I would expect the material in the current paper to be included in the final 
publication, rather than in a separate protocol paper that seems to have been written 
essentially contemporaneously with the final work. I will not second-guess this decision, but 
will instead comment as if the project were not now largely complete. 
 
Response 1 
Thank you for raising this point. This protocol paper gives much more detail on the methods 
than will be contained in the results paper hence the importance of this protocol paper. 
 
There are several factors that contributed to the submission of the protocol at this time:
The evolving nature of the PSP process and the decisions that needed to be made by 
the steering group as the study progresses through to the later stages. 
 
1. 
Discussions with F1000/ HRB Open Research on affiliation of public partner authors 
and the time to agree same. 
 
2. 
Attempts were made to be submit the protocol prior to the completion of the 
workshop but due to an issue with submission process, this was not possible until 
after the workshop had been completed (issue rectified by HRB Open Research).
3. 
Although the protocol would ideally have been submitted at an earlier stage, this was not 
possible given the above factors. 
 
We have retained future tense in keeping with protocols papers but have added the 
following to the paper to be more transparent: 
 
'This protocol was submitted prior to the consensus workshops and published after 
completion of the final prioritisation workshop. There are several factors that contributed to 
the late submission of the protocol. We had to balance the evolving nature of the PSP 
processes and having sufficient clarity on processes for inclusion in a protocol. We also 
encountered delays due to useful discussions with F1000/ HRB Open Research on affiliation 
of public partner authors and technical problems with submission attempts prior to the 
consensus workshop’ (4th paragraph under heading ‘James Lind Alliance PSP process’) 
 
Reviewer Comment 2 
There are a few places where I believe that the reader’s understanding of the project could 
be improved by including either tables or supplementary material to improve the specificity 
of the document. The document states that: 
"Membership of the Steering Group will include individuals and representatives from 
organisations, including patients and the public, reviewers, researchers, clinicians, 
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Either the membership of this Steering group should be provided, or the types of groups 
and organizations that were contacted to participate should be provided. Were these 
groups restricted to Ireland, or to Europe, or to English speaking countries, or to advanced 
economies? It seems likely that the ultimate product coming from a Eurocentric steering 
committee will be different than that which involves individuals from Asia, Africa, and South 
America. On the other hand, it would be difficult to adequately represent researchers, 
clinicians, policymakers, and funders across a wide geographic distribution 
 
Response 2 
We do understand the relevance of the membership of the steering group; however we 
haven’t included detailed information on the steering group here as information on the 
areas of expertise associated with steering group members will be described in detail in the 
results paper that presents the outcome of each of the seven stages of the priority setting 
process. 
 
Thank you for raising this point- we confirm that the steering group members are drawn 
from a wide geographical spread- this has now been highlighted within the text (2nd 
paragraph under heading ‘Establishing the Steering Group’). Given the international 
relevance of the topic, as you have highlighted, it is very important that Priority III steering 
group members were not restricted to Ireland, Europe, English speaking countries, or 
advanced economies. 
 
Reviewer Comment 3  
The areas of expertise associated with steering group members (statistics, survey 
methodology, etc.) should be described in more detail. 
 
Response 3 
Thank you very much for suggesting. We haven’t included detailed information on the 
steering group here as information on the areas of expertise associated with steering group 
members will be described in detail in the results paper that presents the outcome of each 
of the seven stages of the priority setting process. 
 
Reviewer Comment 4 
Similarly, the nature of the “partners” should also be better defined, as should a bit about 
the total number of stakeholders expected to participate. The final report should include 
information on the nature and number of stakeholders that were contacted and who 
declined to participate 
 
Response 4 
Thank you very much for suggesting this. We have now added further information on the 
nature of partners (first line under heading ‘Identifying and inviting potential partners’). 
 
We agree fully that the final report should include information on the nature and number of 
stakeholders that were contacted and who declined to participate.  
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Competing Interests: No competing interests were disclosed.
Reviewer Report 23 September 2021
https://doi.org/10.21956/hrbopenres.14503.r30257
© 2021 Staley K. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Kristina Staley  
TwoCan Associates, Ross-on-Wye, UK 
This is a clear summary of the approach taken to identify priorities for research on rapid reviews. 
It is consistent with the standard JLA approach and is well-described. I do not have any concerns 
about this. I’m not an expert on rapid reviews, so I can’t comment on that. 
 
I am interested in specifics about how well the involvement works, what kind of questions come 
forward and how possible tensions may be resolved between different stakeholders' views on 
what's important. But as no results have yet been reported, these questions are not yet relevant.
 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Patient and public involvement in research
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard.
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